Covered recipient · General Payments record
GREGORY A VIDAL
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$79,556.00
111 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $51,236.00 | 28 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,550.00 | 5 |
| Travel and Lodging | $6,357.35 | 14 |
| Food and Beverage | $3,363.58 | 52 |
| Long term medical supply or device loan | $1,049.07 | 12 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $21,299.66 | 38 |
| AstraZeneca Pharmaceuticals LP | $15,949.67 | 16 |
| Genentech, Inc. | $12,092.10 | 13 |
| Novartis Pharmaceuticals Corporation | $9,991.71 | 18 |
| Eli Lilly and Company | $8,400.00 | 3 |
| TerSera Therapeutics LLC | $4,783.69 | 10 |
| Lilly USA, LLC | $2,400.00 | 1 |
| PFIZER INC. | $2,313.06 | 3 |
| AstraZeneca UK Limited | $1,995.00 | 1 |
| Caris MPI, Inc. | $156.31 | 2 |
| Stemline Therapeutics Inc. | $89.62 | 2 |
| Celgene Corporation | $30.51 | 1 |
| Merck Sharp & Dohme LLC | $22.22 | 1 |
| Coherus Oncology, Inc. | $17.89 | 1 |
| Daiichi Sankyo Inc. | $14.56 | 1 |
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GREGORY A VIDAL
NPI 1730403072 · CMS profile ID 811252
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
GERMANTOWN, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GREGORY A VIDAL, NPI 1730403072, CMS profile ID 811252. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). GREGORY A VIDAL, NPI 1730403072, CMS profile ID 811252. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- GREGORY A VIDAL, NPI 1730403072, CMS profile ID 811252, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
111 matching records · $79,556.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–111 of 111.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $95.20 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234403555 | CMS |
| Gilead Sciences, Inc. | $200.59 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234374926 | CMS |
| Gilead Sciences, Inc. | $58.64 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234411876 | CMS |
| Gilead Sciences, Inc. | $22.50 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234499809 | CMS |
| Gilead Sciences, Inc. | $36.74 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234416317 | CMS |
| Gilead Sciences, Inc. | $19.26 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234536108 | CMS |
| Gilead Sciences, Inc. | $851.97 | 01/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234364157 | CMS |
| Gilead Sciences, Inc. | $489.81 | 01/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234365999 | CMS |
| Novartis Pharmaceuticals Corporation | $99.70 | 01/23/2025 | Long term medical supply or device loan | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200541770 | CMS |
| PFIZER INC. | $7.15 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231330818 | CMS |
| Coherus Oncology, Inc. | $17.89 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235234533 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $8,123.48 | 5 |
| PY2025 | Principal investigator | $3,241,032.45 | 262 |
| PY2024 | Recipient | $3,619.00 | 1 |
| PY2024 | Principal investigator | $3,487,689.84 | 128 |
| PY2023 | Recipient | $1,594.25 | 3 |
| PY2023 | Principal investigator | $2,664,891.60 | 124 |
| PY2022 | Principal investigator | $1,790,974.97 | 79 |
| PY2021 | Recipient | $792.10 | 2 |
| PY2021 | Principal investigator | $283,779.40 | 43 |
| PY2020 | Recipient | $11,229.20 | 2 |
| PY2020 | Principal investigator | $320,975.85 | 71 |
| PY2019 | Recipient | $10,778.50 | 1 |
| PY2019 | Principal investigator | $367,709.52 | 66 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
267 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $171,801.20 | 12/31/2025 | Non-covered Recipient Entity West Cancer Center and Research Institute | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received | No dispute reported | 06/30/2026 | 1232924222 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,002.44 | 12/31/2025 | Non-covered Recipient Entity The West Clinic, P.C. | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC | No dispute reported | 06/30/2026 | 1232925635 |
| Principal investigator 1 | Genentech, Inc. | $8,252.00 | 12/22/2025 | Non-covered Recipient Entity The West Clinic PLLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671804 |
| Principal investigator 1 | BioNTech SE | $8,806.50 | 12/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016630 |
| Principal investigator 1 | BioNTech SE | $2,000.00 | 12/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016672 |
| Principal investigator 1 | BioNTech SE | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016674 |
| Principal investigator 1 | BioNTech SE | $2,078.00 | 12/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016676 |
| Principal investigator 1 | BioNTech SE | $10,000.00 | 12/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016678 |
| Principal investigator 1 | Genentech, Inc. | $2,400.00 | 12/15/2025 | Non-covered Recipient Entity The West Clinic PLLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211671769 |
| Recipient | F. Hoffmann-La Roche AG | $503.68 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211535922 |
| Recipient | F. Hoffmann-La Roche AG | $292.89 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211535926 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $165.00 | 12/12/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672125 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,283.40 | 12/12/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672127 |
| Principal investigator 1 | BioNTech SE | $5,159.70 | 12/11/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016626 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,148.20 | 12/10/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211672002 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $10,222.00 | 12/05/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211672008 |
| Principal investigator 1 | BioNTech SE | $21,528.90 | 12/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016620 |
| Principal investigator 1 | Genentech, Inc. | $26,136.00 | 12/01/2025 | Non-covered Recipient Entity The West Clinic PLLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671800 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,531.00 | 11/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671993 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $295.00 | 11/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671998 |
| Principal investigator 1 | BioNTech SE | $910.00 | 11/25/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016640 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 11/25/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016656 |
| Principal investigator 1 | BioNTech SE | $473.00 | 11/25/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016664 |
| Principal investigator 1 | BioNTech SE | $300.00 | 11/25/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016668 |
| Principal investigator 1 | BioNTech SE | $2,100.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016642 |
| Principal investigator 1 | BioNTech SE | $1,728.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016646 |
| Principal investigator 1 | BioNTech SE | $455.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016648 |
| Principal investigator 1 | BioNTech SE | $1,182.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016650 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016654 |
| Principal investigator 1 | BioNTech SE | $31,550.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016658 |
| Principal investigator 1 | BioNTech SE | $473.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016662 |
| Principal investigator 1 | BioNTech SE | $150.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016666 |
| Principal investigator 1 | BioNTech SE | $8,000.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016670 |
| Principal investigator 1 | BioNTech SE | $4,670.10 | 11/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016628 |
| Principal investigator 1 | Genentech, Inc. | $10,843.00 | 11/13/2025 | Non-covered Recipient Entity The West Clinic PLLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671796 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 11/12/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671730 |
| Principal investigator 1 | Genentech, Inc. | $79.00 | 11/12/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671742 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,148.20 | 11/12/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671990 |
| Principal investigator 1 | BioNTech SE | $14,517.90 | 11/07/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016622 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 11/07/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016652 |
| Principal investigator 1 | BioNTech SE | $473.00 | 11/07/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016660 |
| Principal investigator 1 | Genentech, Inc. | $763.00 | 11/06/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671727 |
| Principal investigator 1 | Genentech, Inc. | $18,069.00 | 11/05/2025 | Non-covered Recipient Entity The West Clinic PLLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671792 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,896.00 | 11/05/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672120 |
| Principal investigator 1 | BioNTech SE | $92.00 | 11/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016680 |
| Principal investigator 1 | BioNTech SE | $92.00 | 11/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016682 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,283.40 | 10/31/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672099 |
| Principal investigator 1 | Genentech, Inc. | $6,750.00 | 10/30/2025 | Non-covered Recipient Entity The West Clinic PLLC | Not supplied | No dispute reported | 06/30/2026 | 1211671785 |
| Principal investigator 1 | BioNTech SE | $4,309.20 | 10/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016634 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $9,963.00 | 10/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671981 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $461.00 | 10/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671988 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $5,125.00 | 10/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672116 |
| Principal investigator 1 | BioNTech SE | $14,524.20 | 10/23/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016632 |
| Principal investigator 1 | Genentech, Inc. | $14,014.00 | 10/23/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671716 |
| Principal investigator 1 | Genentech, Inc. | $2,964.00 | 10/20/2025 | Non-covered Recipient Entity The West Clinic PLLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211671767 |
| Principal investigator 1 | Genentech, Inc. | $853.00 | 10/20/2025 | Non-covered Recipient Entity The West Clinic PLLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671789 |
| Recipient | F. Hoffmann-La Roche AG | $1,225.57 | 10/18/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211535930 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,668.50 | 10/15/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672109 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,516.00 | 10/10/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672104 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $11,298.00 | 10/10/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672112 |
| Principal investigator 1 | BioNTech SE | $3,442.50 | 10/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016624 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,247.10 | 10/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671984 |
| Principal investigator 1 | BioNTech SE | $5,719.98 | 10/03/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016636 |
| Principal investigator 1 | BioNTech SE | $2,385.00 | 10/03/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327 | No dispute reported | 06/30/2026 | 1249016644 |
| Principal investigator 1 | Genentech, Inc. | $11,214.00 | 10/03/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684942 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,655.52 | 10/02/2025 | Non-covered Recipient Entity WEST CANCER CENTER | A Phase 1b Multicentre Openlabel Modular Dose finding and Dose expansion Study to Explore the Safety Tolerability Pharmacokinetics and Anti tumour Activity of Trastuzumab Deruxtecan TDXd in Combination with Other Anticancer Agents in Patients with Metastatic HER2low Breast Cancer DESTINY Breast08 | No dispute reported | 06/30/2026 | 1185548083 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $9,552.00 | 09/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671966 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 09/25/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671699 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $235.00 | 09/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671915 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,167.00 | 09/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671919 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $19,940.00 | 09/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671931 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $161.00 | 09/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671945 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,573.00 | 09/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671954 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,385.10 | 09/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672076 |
| Principal investigator 1 | BioNTech SE | $13,131.00 | 09/23/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016774 |
| Principal investigator 1 | BioNTech SE | $2,658.60 | 09/18/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016770 |
| Principal investigator 1 | Genentech, Inc. | $39.00 | 09/18/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671705 |
| Principal investigator 1 | Genentech, Inc. | $9,476.00 | 09/18/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684932 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $45,303.84 | 09/17/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192098900 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226,519.20 | 09/17/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192188799 |
| Principal investigator 1 | Genentech, Inc. | $12,094.00 | 09/11/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684860 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $176.00 | 09/10/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672095 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $161.00 | 09/05/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671940 |
| Principal investigator 1 | BioNTech SE | $11,986.20 | 09/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016758 |
| Principal investigator 1 | Genentech, Inc. | $34,372.00 | 09/04/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684936 |
| Principal investigator 1 | Genentech, Inc. | $9,812.00 | 09/04/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684938 |
| Principal investigator 1 | Genentech, Inc. | $1,785.00 | 09/02/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684944 |
| Principal investigator 1 | BioNTech SE | $92.00 | 09/01/2025 | Non-covered Recipient Entity The West Clinic, P.C. d/b/a West Cancer Center | BNT327-02 | No dispute reported | 06/30/2026 | 1249011596 |
| Principal investigator 1 | BioNTech SE | $92.00 | 09/01/2025 | Non-covered Recipient Entity The West Clinic, P.C. d/b/a West Cancer Center | BNT327-02 | No dispute reported | 06/30/2026 | 1249011618 |
| Principal investigator 1 | BioNTech SE | $92.00 | 09/01/2025 | Non-covered Recipient Entity The West Clinic, P.C. d/b/a West Cancer Center | BNT327-02 | No dispute reported | 06/30/2026 | 1249011620 |
| Principal investigator 1 | BioNTech SE | $92.00 | 09/01/2025 | Non-covered Recipient Entity The West Clinic, P.C. d/b/a West Cancer Center | BNT327-02 | No dispute reported | 06/30/2026 | 1249011622 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $5,017.00 | 08/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671924 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,036.00 | 08/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671950 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $10,199.00 | 08/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671973 |
| Principal investigator 1 | Genentech, Inc. | $6,020.00 | 08/27/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211684940 |
| Principal investigator 1 | BioNTech SE | $11,402.10 | 08/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016776 |
| Principal investigator 1 | Genentech, Inc. | $20,733.00 | 08/22/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684946 |
| Principal investigator 1 | BioNTech SE | $5,144.40 | 08/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016772 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 08/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016792 |
| Principal investigator 1 | BioNTech SE | $473.00 | 08/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016800 |
| Principal investigator 1 | BioNTech SE | $100.00 | 08/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016808 |
| Principal investigator 1 | Genentech, Inc. | $4,864.00 | 08/20/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211684934 |
| Principal investigator 1 | Genentech, Inc. | $39.00 | 08/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671711 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $560.00 | 08/15/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671969 |
| Principal investigator 1 | BioNTech SE | $455.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016752 |
| Principal investigator 1 | BioNTech SE | $81.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016754 |
| Principal investigator 1 | BioNTech SE | $1,534.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016764 |
| Principal investigator 1 | BioNTech SE | $5,473.80 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016766 |
| Principal investigator 1 | BioNTech SE | $1,423.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016780 |
| Principal investigator 1 | BioNTech SE | $1,218.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016782 |
| Principal investigator 1 | BioNTech SE | $255.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016784 |
| Principal investigator 1 | BioNTech SE | $74.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016786 |
| Principal investigator 1 | BioNTech SE | $4,420.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016790 |
| Principal investigator 1 | BioNTech SE | $1,756.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016798 |
| Principal investigator 1 | BioNTech SE | $900.00 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016806 |
| Principal investigator 1 | BioNTech SE | $5,820.06 | 08/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016812 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,623.50 | 08/13/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671935 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $502.00 | 08/13/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672091 |
| Principal investigator 1 | BioNTech SE | $3,899.70 | 08/07/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016760 |
| Principal investigator 1 | Eli Lilly and Company | $21,018.00 | 08/06/2025 | Non-covered Recipient Entity THE WEST CLINIC | Not supplied | No dispute reported | 06/30/2026 | 1187891114 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14,391.00 | 08/06/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671910 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,195.00 | 08/06/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671958 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $47,177.52 | 08/05/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192098892 |
| Principal investigator 1 | Genentech, Inc. | $1,665.00 | 08/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671680 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,283.40 | 08/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672070 |
| Principal investigator 1 | BioNTech SE | $14,535.90 | 07/31/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016778 |
| Principal investigator 1 | Genentech, Inc. | $741.00 | 07/29/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684858 |
| Principal investigator 1 | Genentech, Inc. | $9,627.00 | 07/25/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684928 |
| Principal investigator 1 | Genentech, Inc. | $1,149.00 | 07/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671690 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $192.00 | 07/23/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672073 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 07/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016794 |
| Principal investigator 1 | BioNTech SE | $473.00 | 07/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016802 |
| Principal investigator 1 | BioNTech SE | $200.00 | 07/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016810 |
| Principal investigator 1 | Genentech, Inc. | $9,235.00 | 07/21/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684930 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $70,766.28 | 07/20/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192098915 |
| Principal investigator 1 | BioNTech SE | $10,656.00 | 07/17/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016768 |
| Principal investigator 1 | Genentech, Inc. | $169.00 | 07/17/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671695 |
| Principal investigator 1 | Genentech, Inc. | $241.00 | 07/14/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684924 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,821.30 | 07/11/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671961 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,459.00 | 07/11/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672081 |
| Principal investigator 1 | BioNTech SE | $8,820.90 | 07/10/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016762 |
| Principal investigator 1 | Genentech, Inc. | $6,809.00 | 07/10/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684856 |
| Principal investigator 1 | Genentech, Inc. | $6,750.00 | 07/09/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Not supplied | No dispute reported | 06/30/2026 | 1211684922 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $60.00 | 07/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671928 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $11,084.00 | 07/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671975 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,474.20 | 07/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672085 |
| Principal investigator 1 | Genentech, Inc. | $17,792.00 | 07/07/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684926 |
| Principal investigator 1 | BioNTech SE | $11,297.70 | 07/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016756 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 07/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016788 |
| Principal investigator 1 | BioNTech SE | $473.00 | 07/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016796 |
| Principal investigator 1 | BioNTech SE | $800.00 | 07/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016804 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14,327.10 | 07/02/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671907 |
| Principal investigator 1 | BioNTech SE | $97.00 | 07/01/2025 | Non-covered Recipient Entity The West Clinic, P.C. d/b/a West Cancer Center | BNT327-02 | No dispute reported | 06/30/2026 | 1249011594 |
| Principal investigator 1 | BioNTech SE | $97.00 | 07/01/2025 | Non-covered Recipient Entity The West Clinic, P.C. d/b/a West Cancer Center | BNT327-02 | No dispute reported | 06/30/2026 | 1249011612 |
| Principal investigator 1 | BioNTech SE | $14,368.50 | 06/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016724 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $641.00 | 06/23/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672031 |
| Principal investigator 1 | BioNTech SE | $10,912.50 | 06/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016722 |
| Principal investigator 1 | BioNTech SE | $300.00 | 06/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016748 |
| Principal investigator 1 | BioNTech SE | $11,040.06 | 06/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016750 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $35,383.14 | 06/18/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192098883 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226,519.20 | 06/18/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192098889 |
| Principal investigator 1 | AstraZeneca UK Limited | $14,788.80 | 06/11/2025 | Non-covered Recipient Entity WEST CANCER CENTER AND RESEARCH INSTITUTE | A Phase 1b Multicentre Openlabel Modular Dose finding and Dose expansion Study to Explore the Safety Tolerability Pharmacokinetics and Anti tumour Activity of Trastuzumab Deruxtecan TDXd in Combination with Other Anticancer Agents in Patients with Metastatic HER2low Breast Cancer DESTINY Breast08 | No dispute reported | 06/30/2026 | 1185548085 |
| Principal investigator 1 | Genentech, Inc. | $612.00 | 06/09/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684902 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $54.00 | 06/06/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672027 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,101.00 | 06/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671878 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $54.00 | 06/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672035 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $261.00 | 06/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,099.80 | 06/02/2025 | Non-covered Recipient Entity West Cancer Center And Research Institute-East Campus | DS8201-A-U301 | No dispute reported | 06/30/2026 | 1223390904 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $32,926.25 | 05/30/2025 | Non-covered Recipient Entity THE WEST CLINIC, PC | IST FACT-2 (WEST CLINIC) DR. VIDAL | No dispute reported | 06/30/2026 | 1251754136 |
| Principal investigator 1 | Genentech, Inc. | $5,676.00 | 05/28/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211684898 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,257.10 | 05/28/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672060 |
| Principal investigator 1 | BioNTech SE | $7,119.00 | 05/27/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016720 |
| Principal investigator 1 | Genentech, Inc. | $9,228.00 | 05/27/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684900 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 05/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016740 |
| Principal investigator 1 | BioNTech SE | $473.00 | 05/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016742 |
| Principal investigator 1 | BioNTech SE | $100.00 | 05/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016744 |
| Principal investigator 1 | BioNTech SE | $5,520.00 | 05/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016746 |
| Principal investigator 1 | Genentech, Inc. | $1,482.00 | 05/21/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684842 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,049.30 | 05/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671874 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $474.00 | 05/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672045 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $6,395.40 | 05/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672049 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $10,649.00 | 05/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672053 |
| Principal investigator 1 | Genentech, Inc. | $2,090.00 | 05/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671631 |
| Principal investigator 1 | Genentech, Inc. | $14,482.00 | 05/19/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684910 |
| Principal investigator 1 | BioNTech SE | $5,492.70 | 05/15/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016718 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $19,341.00 | 05/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671903 |
| Principal investigator 1 | Genentech, Inc. | $33,034.00 | 05/09/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684908 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $308.70 | 05/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672041 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,949.20 | 05/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672066 |
| Principal investigator 1 | BioNTech SE | $1,623.00 | 05/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016726 |
| Principal investigator 1 | BioNTech SE | $6,303.00 | 05/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016728 |
| Principal investigator 1 | BioNTech SE | $2,228.00 | 05/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016730 |
| Principal investigator 1 | BioNTech SE | $2,207.56 | 05/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016732 |
| Principal investigator 1 | BioNTech SE | $293.00 | 05/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016734 |
| Principal investigator 1 | BioNTech SE | $3,963.00 | 05/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016736 |
| Principal investigator 1 | BioNTech SE | $473.00 | 05/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016738 |
| Recipient | F. Hoffmann-La Roche AG | $3,050.67 | 05/08/2025 | Covered Recipient Physician | A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment | No dispute reported | 06/30/2026 | 1211535914 |
| Principal investigator 1 | Genentech, Inc. | $8,420.00 | 05/07/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211684912 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $9,701.00 | 05/07/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671882 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,327.00 | 05/07/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671891 |
| Principal investigator 1 | Genentech, Inc. | $1,087.00 | 05/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671619 |
| Principal investigator 1 | BioNTech SE | $7,219.80 | 04/28/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016716 |
| Principal investigator 1 | Genentech, Inc. | $9,947.00 | 04/25/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684918 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,049.30 | 04/23/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671896 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,101.00 | 04/16/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671886 |
| Principal investigator 1 | BioNTech SE | $5,593.50 | 04/15/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016714 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 04/15/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684852 |
| Principal investigator 1 | Genentech, Inc. | $1,359.00 | 04/14/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684846 |
| Principal investigator 1 | Genentech, Inc. | $1,200.00 | 04/14/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684848 |
| Principal investigator 1 | Genentech, Inc. | $11,688.00 | 04/14/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684916 |
| Principal investigator 1 | Genentech, Inc. | $1,422.00 | 04/11/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684850 |
| Principal investigator 1 | Genentech, Inc. | $1,717.00 | 04/11/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684854 |
| Principal investigator 1 | Genentech, Inc. | $2,964.00 | 04/09/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211684844 |
| Principal investigator 1 | BioNTech SE | $4,734.00 | 04/08/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016712 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,450.00 | 04/04/2025 | Non-covered Recipient Entity ONEONCOLOGY | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) | No dispute reported | 06/30/2026 | 1185548087 |
| Principal investigator 1 | Genentech, Inc. | $563.00 | 04/02/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684920 |
| Principal investigator 1 | BioNTech SE | $4,790.70 | 04/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016710 |
| Principal investigator 1 | Genentech, Inc. | $724.00 | 04/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671611 |
| Recipient | F. Hoffmann-La Roche AG | $3,050.67 | 03/31/2025 | Covered Recipient Physician | A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment | No dispute reported | 06/30/2026 | 1211535918 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,477.62 | 03/28/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | No dispute reported | 06/30/2026 | 1185548079 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $148.00 | 03/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671836 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,188.00 | 03/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671841 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $507.00 | 03/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671846 |
| Principal investigator 1 | BioNTech SE | $7,119.00 | 03/25/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016700 |
| Principal investigator 1 | BioNTech SE | $5,492.70 | 03/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016698 |
| Principal investigator 1 | BioNTech SE | $3,680.00 | 03/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016708 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,079.80 | 03/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671832 |
| Principal investigator 1 | Genentech, Inc. | $4,815.00 | 03/18/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211684914 |
| Principal investigator 1 | Genentech, Inc. | $6,750.00 | 03/17/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Not supplied | No dispute reported | 06/30/2026 | 1211684896 |
| Principal investigator 1 | BioNTech SE | $7,877.70 | 03/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016696 |
| Principal investigator 1 | Genentech, Inc. | $14,976.00 | 03/14/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211684906 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $60.00 | 03/12/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671858 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $292.50 | 03/12/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672023 |
| Principal investigator 1 | BioNTech SE | $5,356.80 | 03/11/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016694 |
| Principal investigator 1 | Eli Lilly and Company | $2,932.00 | 03/10/2025 | Non-covered Recipient Entity THE WEST CLINIC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187891908 |
| Principal investigator 1 | BioNTech SE | $2,549.70 | 03/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016692 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $422.00 | 02/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671808 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $21,094.00 | 02/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671863 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $674.00 | 02/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671869 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,427.00 | 02/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671819 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,037.60 | 02/19/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671828 |
| Principal investigator 1 | BioNTech SE | $24,798.60 | 02/18/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016690 |
| Principal investigator 1 | Genentech, Inc. | $8,275.00 | 02/18/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671635 |
| Principal investigator 1 | BioNTech SE | $6,936.30 | 02/05/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016688 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $13,720.00 | 02/05/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672019 |
| Principal investigator 1 | Genentech, Inc. | $1,234.00 | 02/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671582 |
| Principal investigator 1 | Genentech, Inc. | $18,512.00 | 02/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671638 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $9,147.00 | 01/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671815 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $490.00 | 01/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671823 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,050.00 | 01/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671855 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $32,333.00 | 01/29/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671866 |
| Principal investigator 1 | Eli Lilly and Company | $71,692.00 | 01/28/2025 | Non-covered Recipient Entity THE WEST CLINIC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187891574 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,030.50 | 01/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671811 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,030.00 | 01/22/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211672015 |
| Principal investigator 1 | Genentech, Inc. | $1,728.00 | 01/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211671594 |
| Principal investigator 1 | Genentech, Inc. | $5,045.00 | 01/21/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211684904 |
| Principal investigator 1 | BioNTech SE | $4,977.90 | 01/17/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016686 |
| Principal investigator 1 | Genentech, Inc. | $6,750.00 | 01/16/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Not supplied | No dispute reported | 06/30/2026 | 1211684894 |
| Principal investigator 1 | Genentech, Inc. | $563.00 | 01/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211671642 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,063.70 | 01/13/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211671852 |
| Principal investigator 1 | BioNTech SE | $1,816.00 | 01/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016702 |
| Principal investigator 1 | BioNTech SE | $122.00 | 01/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016704 |
| Principal investigator 1 | BioNTech SE | $1,013.00 | 01/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016706 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $181,215.36 | 01/09/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192188803 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $770,165.25 | 01/08/2025 | Non-covered Recipient Entity WEST CANCER CENTER | 0000000000000000000000000000000000000000000000000000000000000000214360 | No dispute reported | 06/30/2026 | 1192098906 |
| Principal investigator 1 | BioNTech SE | $8,016.30 | 01/07/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | BNT327-02 | No dispute reported | 06/30/2026 | 1249016684 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $38,319.87 | 01/03/2025 | Non-covered Recipient Entity WEST CANCER CENTER | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185548077 |